Bard Associates Inc. Maintains Position in Akers Biosciences Inc (AKER)
Bard Associates Inc. held its stake in shares of Akers Biosciences Inc (NASDAQ:AKER) during the second quarter, according to its most recent filing with the SEC. The firm owned 161,700 shares of the medical instruments supplier’s stock at the close of the second quarter. Bard Associates Inc. owned 1.82% of Akers Biosciences worth $202,000 as of its most recent filing with the SEC.
Akers Biosciences Inc (NASDAQ:AKER) opened at 0.997 on Wednesday. The company’s market capitalization is $8.87 million. The firm has a 50-day moving average of $1.00 and a 200 day moving average of $1.32. Akers Biosciences Inc has a 12-month low of $0.85 and a 12-month high of $3.60.
Akers Biosciences (NASDAQ:AKER) last announced its quarterly earnings data on Monday, August 14th. The medical instruments supplier reported ($0.08) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.04). The firm had revenue of $1.20 million during the quarter. Akers Biosciences had a negative net margin of 89.49% and a negative return on equity of 59.94%. Analysts expect that Akers Biosciences Inc will post ($0.25) EPS for the current fiscal year.
Separately, ValuEngine cut shares of Akers Biosciences from a “hold” rating to a “sell” rating in a research note on Thursday, May 18th.
Akers Biosciences Profile
Akers Biosciences, Inc, together with its subsidiaries, develops, manufactures, and supplies rapid screening and testing products designed to deliver healthcare information to healthcare providers and consumers in the United States and internationally. The companys marketed products include BreathScan, a disposable breath alcohol detector; BreathScan PRO, a quantitative breath alcohol detection system; METRON, a disposable breath ketone device to monitor ketosis; and BreathScan Lync, a non-invasive, quantitative measurement of biological markers for health and wellness.
Receive News & Stock Ratings for Akers Biosciences Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akers Biosciences Inc and related stocks with our FREE daily email newsletter.